Wakamoto Pharmaceutical Co., Ltd. operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Wakamoto Pharmaceutical Co., Ltd. with three other
companies in this sector in Japan:
Biofermin Pharmaceutical Company Limited
sales of 10.62 billion Japanese Yen [US$96.31 million]
of which 62%
was New BioferminS),
Koei Chemical Company, Limited
(17.28 billion Japanese Yen [US$156.72 million]
I'rom Group Co Ltd
(4.89 billion Japanese Yen [US$44.35 million]
of which 74%
was Smo Business).
Wakamoto Pharmaceutical Co., Ltd. reported sales of ¥10.83 billion (US$98.23 million)
March of 2017.
decrease of 3.2%
versus 2016, when the company's sales were ¥11.18 billion.
Contributing to the drop in overall sales was the 7.2% decline
in Specified Sales Bussiness, from ¥2.31 billion to ¥2.14 billion.
There were also decreases in sales in
Medical Pharmaceutical Products (down 1.2% to ¥5.69 billion)
Drugs (down 4.0% to ¥2.82 billion)
Other Businesses (down 0.8% to ¥183.81 million)